Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014

Reif, Sharon; Creedon, Timothy B.; Horgan, Constance M.; Stewart, Maureen T.; Garnick, Deborah W.

doi:10.1080/02791072.2017.1300360

Cited by 20 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While our work and others do not support any claims of significant harm from insurance expansion with regard to the opioid epidemic, there is ample evidence of benefit with regard to increased health insurance coverage among uninsured young adults suffering from substance use disorders and decreased out-of-pocket spending on substance use treatment. 9,[30][31][32][33]…”

Section: Discussionmentioning

confidence: 99%

Impact of the Young Adult Dependent Coverage Expansion on Opioid Overdoses and Deaths: a Quasi-Experimental Study

et al. 2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Impact of the Young Adult Dependent Coverage Expansion on Opioid Overdoses and Deaths: a Quasi-Experimental Study

et al. 2020

View full text Add to dashboard Cite

“…In addition, the Medicare program does not currently cover treatment services delivered in OTPs, which greatly limits access to methadone for this growing segment of the population. Private insurers also place similar limits on buprenorphine and methadone treatment for opioid use disorder [164].…”

Section: Availability Of Buprenorphine-waivered Providers In the Usamentioning

confidence: 99%

Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA

et al. 2020

View full text Add to dashboard Cite

Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medications in the specialty substance use disorder treatment system, other treatment settings and systems, and among providers with a federal waiver to prescribe buprenorphine. We also present the most current data on the availability of alcohol and opioid use disorder medications in the USA. These estimates show steady growth in availability of opioid use disorder medications over the past decade and a decline in availability of alcohol use disorder medications. However, overall use of medications in the USA remains low. In 2017, only 16.3% of specialty treatment programs offered any single medication for alcohol use disorder treatment and 35.5% offered any single medication for opioid use disorder treatment. Availability of buprenorphine-waivered providers has increased significantly since 2002. However, geographic disparities in access to buprenorphine remain. Some of the most promising strategies to increase availability of alcohol and opioid use disorder medications include the following: incorporating substance use disorder training in healthcare education programs, educating the substance use disorder workforce about the benefits of medication treatment, reducing stigma surrounding the use of medications, implementing medications in primary care settings, implementing integrated care models, revising regulations on methadone and buprenorphine, improving health insurance coverage of medications, and developing novel medications for the treatment of substance use disorder.

show abstract

“…Third, while buprenorphine is available in most commercial insurance plans, insurers often restrict access to MAT by placing drugs such as buprenorphine on the highest cost-sharing tier. 6 …”

mentioning

confidence: 99%

Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder

2017

View full text Add to dashboard Cite

appendectomy. 15 Tanaka et al 15 presented their single-institution experience with 55 children with ultrasonography-identified complex appendicitis with phlegmon or abscess managed nonoperatively. In patients who did not return for interval appendectomy, recurrence of appendicitis occurred in 34.2% and was independent of whether an appendicolith was present. 15 Complicated appendicitis contributes disproportionately to the cumulative cost burden of appendicitis both individually and from a population perspective. It is a significant source of morbidity for previously healthy children. Preventive efforts have not resulted in reduced rates of complex disease over the years, nor have rates of complex disease increased with relatively widespread adoption of the practice of urgent rather than emergency appendectomy. Strong evidence exists supporting therapeutic antibiotic management, whether as an adjunct or definitive therapy. Serres and colleagues 2 present a thoughtful analysis using patientcentric outcomes that offers compelling support for the safety of appendectomy performed at a prompt time (within 24 hours of presentation) in a way that optimally uses existing hospital and operating room resources. They acknowledge the potential for a relatively small increase in hospital length of stay. Ultimately, the patient's clinical status combined with the availability of resources rather than differentiated patient outcomes define optimal management strategy for this problem for an individual institution.

show abstract

Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014

Cited by 20 publications

References 29 publications

Impact of the Young Adult Dependent Coverage Expansion on Opioid Overdoses and Deaths: a Quasi-Experimental Study

Impact of the Young Adult Dependent Coverage Expansion on Opioid Overdoses and Deaths: a Quasi-Experimental Study

Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA

Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder

Contact Info

Product

Resources

About